ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has entered into a licensing and research collaboration agreement with Nanyang Technological University, Singapore (NTU Singapore) for the development of Modybodies, a novel type of stabilised heavy chain monoclonal antibody (mAb) fragments.

For more information, please refer to the English or Chinese press release.